CAMBRIDGE, Mass., Feb. 9 /PRNewswire-FirstCall/ -- ViaCell, Inc. will announce its 2005 year-end financial results on February 23, 2006 before the opening of U.S. financial markets. In connection with this announcement, ViaCell will host a conference call and live audio webcast on February 23, 2006 at 10:00 a.m. Eastern Time to discuss its 2005 financial results and outlook for 2006 as well as its business activities.
Participants may access the call by dialing (913) 981-4901. This call will also be broadcast live over the Internet at http://www.viacellinc.com under the Investor Information section. Please dial in 5 to 10 minutes prior to the scheduled conference call time or log on to the website at least 15 minutes prior to the call in order to register, download, and install any necessary software.
A replay of this conference call will be available for two weeks, beginning Thursday, February 23, 2006 at 1:00 p.m. Eastern Time by dialing (719) 457-0820 and using the access code 7285741. In addition, a replay of the webcast will be archived on the ViaCell website in the Investor Information section.
About ViaCell
ViaCell is a biotechnology company focused on enabling the widespread use of human cells as medicine. The Company is developing a pipeline of proprietary stem cell product candidates intended to address cancer, cardiac disease, and diabetes. CB001, its lead cord blood derived stem cell therapy product, is being developed for hematopoietic stem cell transplantation in patients affected by a variety of cancers. In addition to its therapeutic development programs, ViaCell’s reproductive health business unit commercializes ViaCord(R), a product that offers expecting families the option of preserving their baby’s umbilical cord blood. The company is working to leverage its commercial infrastructure and product development capabilities by developing ViaCyte(SM), its investigational product intended to broaden reproductive choices for women through the cryopreservation of human unfertilized eggs. ViaCell is headquartered in Cambridge, Massachusetts with a processing and storage facility in Kentucky and additional research and development operations in Singapore.
ViaCell(R) and ViaCord(R) are registered trademarks and ViaCyte(SM) is a service mark of ViaCell, Inc.
For More Information Contact: Justine E. Koenigsberg Senior Director, Corporate Communications (617) 914-3494
ViaCell, Inc.
CONTACT: Justine E. Koenigsberg, Senior Director, Corporate Communicationsat ViaCell, Inc., +1-617-914-3494
Web site: http://www.viacellinc.com/
